Literature DB >> 22614116

The relationship of Akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone.

F Seemüller1, U Lewitzka, M Bauer, S Meyer, R Musil, R Schennach, M Riedel, S Doucette, H-J Möller.   

Abstract

Akathisia as well as younger age, early illness onset and discharge are important risk factors for suicidality in patients with first-episode schizophrenia. The aim of the present study was to analyze on a single case basis the relationship between a sudden increase in suicidality, anxiety symptoms, medication dosing and clinician- and patient-rated akathisia. A small subsample of patients demonstrated a positive relationship between suicidality and akathisia scores within the titration period of the study medication. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614116     DOI: 10.1055/s-0032-1309004

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  4 in total

1.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

Review 2.  Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment.

Authors:  Leonardo Tondo; Ross J Baldessarini
Journal:  Curr Psychiatry Rep       Date:  2016-09       Impact factor: 5.285

Review 3.  The Relationship Between Antipsychotic-Induced Akathisia and Suicidal Behaviour: A Systematic Review.

Authors:  Arturas Kalniunas; Ipsita Chakrabarti; Rakhee Mandalia; Jasna Munjiza; Sofia Pappa
Journal:  Neuropsychiatr Dis Treat       Date:  2021-12-03       Impact factor: 2.570

4.  Amisulpride withdrawal akathisia responding to aripiprazole with propranolol in first-onset psychosis: a case report.

Authors:  Hae-Jung Yang; Seung-Gon Kim; Eun Hyun Seo; Hyung-Jun Yoon
Journal:  BMC Psychiatry       Date:  2022-01-29       Impact factor: 3.630

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.